

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0015
Drug name and formulations:	Niquitin® oral film 2.5mg

Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	No evidence it is less safe than alternative NRT products.
Clinical effectiveness	<i>Established licensed product</i>	Established licensed product.
Strength of evidence		Available data support the bioequivalence of 2.5mg oral strips to 2mg nicotine lozenges, for which efficacy has been determined.
Cost effectiveness or resource impact	£	Niquitin strips are more costly than 2mg nicotine lozenges and gum; however they are less costly than nicotine inhalator, sprays and sublingual tablets.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	Another option in NRT treatment.
National guidance and priorities	<i>NICE, MTRAC</i>	NICE Public Health Guidance 10 (2008) "Smoking Cessation Services in Primary Care" makes no distinction between NRT products.
Local health priorities	<i>CCG views</i>	Smoking Cessation is an important issue for CCGs.
Equity of access	<i>Equality assessment</i>	No restrictions
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	

Formulary status (RAG) and rationale	GREEN- NRT is already included on APC formulary, NICE makes no distinction between NRT products/ delivery systems.
Implementation requirements:	
Implementation monitoring:	